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Background: The reproducibility of cardiopulmonary exercise testing (CPET) has not been established in young cystic ﬁbrosis (CF) patients using
a valid protocol.
Methods: Thirteen 7–18 year olds completed three CPETs, separated by 48 h and 4–6 weeks. CPET involved a ramp-incremental cycling test
with supramaximal veriﬁcation.
Results: Maximal oxygen uptake was repeatedly determined with no learning effect and typical errors expressed as a coefﬁcient of variation
(TECV%) of 9.3% (48 h) and 13.3% (4–6 weeks). The reproducibility of additional parameters of aerobic function [gas exchange threshold
(TECV%: 11.2%, 16.8%); _VO2 mean response time (TECV%: 37.8%, 89.4%); _VO2 gain (TECV%: 17.4%, 24.5%)] and clinical utility [e.g. SaO2%
(TECV%: 2.2%, 3.1%); ventilatory drive ( _VE/ _VCO2-slope) (TECV%: 7.8%, 17.7%)] was also established over the short- and the medium-term,
respectively.
Conclusion: These results establish limits of variability to determine meaningful changes over the short- and the medium-term for CPET outcomes
in young CF patients.
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A cardiopulmonary exercise test (CPET) is considered the
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http://dx.doi.org/10.1016/j.jcf.2013.04.012oxygen uptake ( _VO2max)] in patients with mild-to-moderate
cystic fibrosis (CF). The European CF Society (ECFS) Exercise
Working Group recently promoted CPET as the exercise testing
method of choice for this patient group. Moreover, the ECFS
Clinical Trials Network Standardisation Committee has called
for assessment of the validity, reproducibility and feasibility of
outcome measures utilised in CF and advocated research into
the most appropriate exercise test for paediatric patients [1].
Recently, our research group presented a combined incre-
mental and supramaximal (Smax) verification CPET protocol,
which is superior at determining valid _VO2max in young CF
patients compared to a ramp only protocol [2]. _VO2max is
currently the principle outcome from a CPET, as it has been
shown to be an independent predictor of CF patient mortality
[3]. However, a more comprehensive evaluation of patients'
cardiorespiratory fitness may be gained from CPET, through the
quantification of submaximal parameters of aerobic (lactateby Elsevier B.V. All rights reserved.
Table 1
Patients' baseline anthropometric and pulmonary function data upon initiation
into the study (n = 13; 4 females).
Variable Value (mean ± SD) Range
Age (years) 12.81 ± 3.26 7.57–18.44
Stature (m) 1.53 ± 0.16 1.23–1.74
Body mass (kg) 50.89 ± 17.26 24.35–83.50
BMI (kg·m2) 21.18 ± 3.86 14.19–28.24
SSkF (mm) 43 ± 13 24–67
Gender m = 9, f = 4 –
CFTR genotype – –
Homozygote ΔF508 9 –
ΔF508/P67L 1 –
ΔF508/621 + IG → T 1 –
ΔF508/2184delA 1 –
ΔF508/G55ID 1 –
Chronic P. Aeruginosa
infection a
“Chronic”, n = 2; “Free”, n = 5
“Intermittent”, n = 4 “Never”, n = 2
Shwachman score 82 ± 6 67–91
Northern score b 4 ± 1 2–6
FVC [% predicted (L)] 103.5 ± 15.0 (3.3 ± 1.2) 79.0–127.0 (1.6–5.1)
FEV1 [% predicted (L)] 91.7 ± 17.8 (2.7 ± 1.0) 65.0–120.0 (1.4–4.1)
Values are means ± SD, with the range also displayed where suitable, unless
otherwise stated.
BMI, body mass index; SSkF, sum of skinfolds; CFTR, cystic fibrosis
transmembrane conductance regulator; P. Aeruginosa; Pseudomonas Aeruginosa;
Shwachman score — scoring 4 separate aspects of the disease profile; general
activity; physical examination; nutritional status; and chest radiographic findings,
using the most recent clinical review information. A total of 100 points represents a
perfect score of health; FVC, forced vital capacity; FEV1, forced expiratory
volume in 1-s.
a According to Leeds Criteria, “chronic”, N50% of the preceding 12 months were
P. aeruginosa culture positive; “intermittent”, ≤50% of the preceding 12 months
were P. aeruginosa culture positive; “never”, no growth of P. aeruginosa for the
previous 12 months, having previously been P. aeruginosa culture positive; “free”,
P. aeruginosa has never been cultured.
b Provides evidence of radiographic chest ﬁndings. Maximum score is 20,
with 20 being the most severe.
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ventilatory ( _VE/ _VCO2-slope and oxygen uptake efficiency slope
(OUES) [4]) function. Submaximal outcomes may be especially
useful in the clinical environment, as patients may not be able or
willing to provide a maximal effort.
Unfortunately, insufficient data exists regarding the reproduc-
ibility of CPET in CF patients and that which does exist has
utilised testing protocols which cannot verify a ‘true’ maximal
effort [e.g. 5,6]. Moreover, the only paediatric study to address this
issue [5] did not measure _VO2max. Quantifying reproducibility
enables researchers and clinicians to understand the variation
associated with outcome measures [7] and to determine meaning-
ful changes [8]. Consequently, inferences regarding therapeutic
interventions or disease-related changes in CPET derived
parameters cannot currently be discerned with certainty in these
patients. Therefore, this study sought to establish the short- (48 h)
and themedium-term (4–6 weeks) reproducibility ofmaximal and
submaximal indicators of cardiorespiratory fitness using our
recently validated CPET protocol.
2. Material and methods
2.1. Study population
Thirteen young patients (Table 1) with mild-to-moderate CF
were recruited from outpatient CF clinics at the Royal Devon
and Exeter NHS Foundation Trust Hospital (RD&E). Inclusion
criteria comprised a CF diagnosis based on clinical features,
sweat chloride N 60 mmol·L−1/100 mg and genotyping. Sta-
ble lung function within 10% of best in the preceding 6 months
and no increase in symptoms or weight loss 2 weeks prior to
testing was obligatory. Unstable non-pulmonary comorbidities
or acute infections warranted exclusion. Disease severity was
graded using the Schwachman score [9] and routine clinical
measurements obtained as part of patients' annual review by
their multidisciplinary CF clinical care team (Table 1). Ethics
approval was granted by the South West NHS Research Ethics
Committee and written informed consent and assent obtained
from parents/guardians and patients, respectively. Patients
arrived at the laboratory in a rested state, at least 2 h post-
prandial and having refrained from caffeine for N2 h. All
patients were instructed to continue maintenance medications
as usual throughout the duration of their study involvement.
2.2. Anthropometry and pulmonary function
Body mass (Seca 220; Vogel & Halke, Hamburg, Germany)
and stature (Seca 220; Vogel & Halke, Hamburg, Germany) were
measured to the nearest 0.01 kg and 0.01 m, respectively, at each
visit. Skin folds were measured to the nearest 1 mm on the
right-hand side of the body at the biceps brachii, tricep, subscapula
and suprailiac regions (Harpenden; British Indicators, Burgess
Hill, UK). Forced vital capacity (FVC) and forced expiratory
volume in 1-s (FEV1) were also assessed at each visit to the
laboratory, using flow-volume loop spirometry (MicroMedical
MicroLoop 3535, Numed, Sheffield, UK). The best of three
consistent exhalations (b5% variability) was recorded, inaccordance with the British Thoracic Society (1994) guidelines.
All lung function measurements were expressed as a percentage
predicted normal, using appropriate reference data [10].2.3. Exercise testing protocol
Following familiarisation, exercise was performed on a cycle
ergometer [Lode Excalibur or Lode Corival, Groningen, The
Netherlands]. The experimental protocol was identical to our
previous study [2], using combined exhaustive ramp-incremental
and Smax verification tests. Following 3-min warm-up (20 W),
patients completed an incremental ramp cycling test, whereby
resistance increased at a predetermined rate (10–25 W·min−1).
Ramp rate was dependent on patients' age, height and fitness
level, to elicit ~8–12 min test durations. Patients maintained
~70–80 rpm until volitional exhaustion, defined as a drop in
cadence N 10 rpm for 5 consecutive seconds despite strong
verbal encouragement. Five minute active (20 W cycling) and
10-min passive seated recovery followed. Smax verification of
_VO2max was then performed, whereby 3-min warm-up (20 W)
preceded a ‘step’ transition to a constant work rate equivalent to
110% peak power output. This work rate was maintained until
Table 2
Patients' physiological responses to CPET during the three visits.
Variable n Test 1 Test 2 Test 3
Maximal exercise parameters
_VO2max (L∙min−1) 13 1.77 (0.57) 1.76 (0.56) 1.68 (0.55)
HRpeak (b∙min−1) 11 190 (12) 186 (14) 186 (19)
SaO2 (%) 13 95 (3) 96 (1) 96 (3)
RPE 13 9 (2) 9 (2) 9 (1)
RPD 13 7 (3) 6 (3) 8 (3)
Ramp peak power output (W) 13 157 (55) 148 (62) 145 (65)
Submaximal parameters
GET (L∙min−1) 12 1.00 (0.22) 0.93 (0.21) 1.05 (0.29)
MRT (s) 11 42 (15) 65 (17) 54 (26)
_VO2 gain (mL·min−1·W−1) 12 8.01 (1.36) 8.11 (1.22) 7.73 (2.64)
OUES100 (mL·min
−1·logL−1) 12 803 (227) 789 (181) 799 (218)
OUESGET (mL·min
−1·logL−1) 12 797 (223) 730 (188) 756 (389)
_VE/ _VCO2-slope 12 34.13 (4.51) 33.26 (3.25) 32.14 (5.39)
_VE/ _VO2 at the GET 12 28.57 (5.45) 28.63 (3.84) 28.09 (4.58)
_VE/ _VCO2 at the GET 12 28.07 (3.96) 29.15 (5.43) 27.95 (5.51)
Values are means ± SD, with the range also displayed unless otherwise stated.
_VO2max, maximal oxygen uptake; HRpeak, peak heart rate; SaO2%, end-exercise
arterial oxygen saturation; RPE, end-exercise rating of perceived exertion; RPD,
end-exercise rating of perceived dyspnoea; ramp; incremental ramp test; GET,
non-invasive estimate of the lactate threshold whichwas verified by the ventilatory
threshold; MRT, mean response time; _VO2 gain, oxygen cost of exercise;
OUES100, oxygen uptake efficiency slope for the entire duration of the ramp test;
OUESGET, OUES to the GET; _VE/ _VCO2-slope, ventilatory drive; _VE/ _VO2,
ventilatory equivalent for oxygen uptake; _VE/ _VCO2, ventilatory equivalent for
carbon dioxide.
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cycling) completed the CPET.
Following test one (T1), all procedures were repeated 48 h
(short-term; T2) and 4–6 weeks (medium-term; T3) later, at a
similar time of day.Medium-term clinical stability was monitored
T1–T3, with disease considered unstable if a pulmonary exacer-
bation developed, a change in pulmonary medications was
required, chest signs on physical examination altered, or a≥10%
decline in pulmonary function was recorded.
2.4. Experimental measures
2.4.1. Gas analysis
Prior to each test, the metabolic cart (Metalyzer 3B Cortex,
Biophysik, Leipzig, Germany) was calibrated using gases of
known concentration, and the turbine volume transducer using
a 3 L calibration syringe (Hans Rudolph, Kansas City, MO).
Breath-by-breath pulmonary gas exchange and ventilation were
measured and averaged to 15-s time bins. The highest 15-s
stationary average _VO2 from the ramp and Smax protocols [2]
represented _VO2max.
2.4.2. Submaximal gas exchange parameters
The LT was non-invasively identified using the gas exchange
threshold (GET) [11] and confirmed through visual inspection of
the ventilatory equivalents for _VO2 and _VCO2 [12]. The _VO2
mean response time (MRT) was determined using the time from
the onset of the ramp test to the intersection point between the
baseline _VO2 and a backward extrapolation of the slope of _VO2 as
a function of time. The _VO2 ‘gain’ (Δ _VO2/ΔWR) was determined
by regression of the ‘linear’ portion of the _VO2 response against
power output. The OUES for the entire exercise duration
(OUES100) and up to the GET (OUESGET) were derived from
the slope of the linear function between _VO2 (mL∙min−1) and log
_VE (L∙min−1) [4]. The _VE/ _VCO2-slope (ventilatory drive) was
calculated using linear regression during the entire CPET [13].
2.4.3. Additional measures
Heart rate (HR) was determined every 5-s (PhysioFlow,
PF-05, Manatec Biomedical, Paris, France), with the highest
15-s value taken as peak HR (HRpeak). Fingertip arterial O2
saturation (SaO2%) was measured on a beat-by-beat basis via
pulse oximetry (NONIN, Avant 4000, NONIN Medical Inc.,
USA). Subjective ratings of perceived exertion (RPE) and
dyspnoea (RPD) were recorded upon exhaustion using the
pictorial children's effort rating table (P-CERT) and the 0–10
category ratio (CR-10) scale, respectively, the methodology for
which is described elsewhere[2].
2.5. Analysis
Data are expressed as means and standard deviations unless
otherwise stated. Reproducibility was assessed using a down-
loadable spreadsheet [14]. Following initial analyses to ensure
distribution normality and heteroscedasticity, paired samples
t-tests examined differences between tests with significance set at
p b 0.05. Change in the mean, intraclass correlation coefficients(ICCs), absolute typical error (TE) and TE expressed as a
percentage of the coefficient of variation (TECV%), were
calculated (with 95% confidence limits) for short- (T1–T2)
(Table 3) and medium-term (T1–T3) pairwise comparisons
(Table 4).
3. Results
One patient was lost to follow-up at T3, due to reasons
unrelated to the study. Table 1 summarises patients' (n = 13)
baseline physical characteristics. Clinical stability was defined by
symptoms, changes in patients' treatment, spirometric variables
and body mass over the course of the study (T1–T3). All patients
remained clinically stable and with no change in symptoms,
treatment, body mass [50.89 (17.26) vs. 50.98 (17.17) kg; p =
0.63], BMI [21.23 (7.79) vs. 21.18 (7.61) kg·m2; p = 0.97] or
lung function [FVC: 3.12 (1.08) vs. 3.03 (1.04) L; p = 0.10;
FEV1: 2.53 (0.88) vs. 2.48 (0.87) L; p = 0.10]. Stability predated
T1 (i.e. recruitment) and was maintained beyond T3.
Maximal and submaximal physiological responses from the
CPET are presented in Table 2. Short- (T1–T2) and medium-
term (T1–T3) reproducibility data from CPET derived measures
are presented in Table 3 and 4 respectively. The reproducibility
for _VO2max is presented in Fig. 1. The GET and OUESGET were
identifiable in all patients at T1 and 12 (92%) patients at T2 and
T3. MRT was detected in 11 (85%) patients from T1–T3.
When compared with this combined approach (ramp and
Smax), _VO2max obtained using the traditional ramp only method
was significantly lower at both T2 [1.76 (0.56) vs. 1.63
Table 3
Short-term (48 h) test–retest reproducibility (T1–T2) of CPET derived measures.
Variable N Change in the mean p-Value TE (95% CL) TECV% (95% CL) ICC p-Value
Lung function
FVC (L) 13 0.01 0.79 0.08 (0.05–0.11) 3.1 (2.3–4.7) 1.00 b0.01
FEV1 (L) 13 −0.02 0.48 0.07 (0.06–0.11) 2.7 (2.0–4.1) 0.99 b0.01
Maximal exercise parameters
_VO2max (L∙min−1) 13 −0.01 0.91 0.15 (0.12–0.23) 9.3 (6.9–14.3) 0.94 b0.01
HRpeak (b∙min−1) 11 −4 0.14 6 (4–9) 3.2 (2.3–5.1) 0.83 b0.01
SaO2 (%) 13 1 0.42 2 (2–3) 2.2 (1.7–3.4) 0.03 0.91
RPE 13 0.1 0.72 0.5 (0.4–0.8) 7.8 (5.8–12.0) 0.91 b0.01
RPD 13 −1.3 0.09 1.7 (1.3–2.6) 63.7 (45.1–111.0) 0.60 0.05
Ramp peak power output (W) 13 −9 0.11 14 (11.21) 21.6 (16.0–34.6) 0.95 b0.01
Submaximal parameters
GET (L∙min−1) 12 −0.06 0.17 0.11 (0.08–0.16) 11.2 (8.2–17.8) 0.80 b0.01
MRT (s) 11 25 b0.01 13 (10–21) 49-1 (34.4–89.0) 0.65 0.05
_VO2 gain (mL·min−1·W−1) 12 0.10 0.84 1.18 (0.84–2.01) 17.4 (12.0–31.2) 0.18 0.62
OUES100 (mL·min
−1·logL−1) 12 −14.12 0.74 100.85 (75.41–156.39) 12.0 (8.9–19.2) 0.79 b0.01
OUESGET (mL·min
−1·logL−1) 12 −67.20 0.23 127.89 (95.63–198.31) 17.9 (13.1–39.1) 0.66 0.03
_VE/ _VCO2-slope 12 −0.88 0.42 2.54 (1.90–3.94) 7.8 (5.8–12.3) 0.63 0.03
_VE/ _VO2 at the GET 12 0.06 0.96 3.19 (2.38–4.94) 10.2 (7.5–16.2) 0.59 0.05
_VE/ _VCO2 at the GET 12 1.09 0.32 2.57 (1.92–3.99) 8.8 (6.5–14.0) 0.75 0.01
Values are reported as means (95% confidence limits). TE, typical error; TECV%, TE expressed as a percentage of the coefficient of variation; ICC, intra-class
correlation coefficient. See Table 2 for list of abbreviations for exercise outcomes.
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(0.54) L·min−1; p = 0.07], with a trend towards significance at
T1 [1.77 (0.57 vs. 1.68 (0.56) L·min
−1; p = 0.07], as has been
previously demonstrated [2]. Moreover, _VO2max using the
combined approach was also associated with smaller error over
both the short-term [TE: 0.15 (0.12–0.23) vs. 0.23 (0.17–
0.38) L·min−1; TECV%: 9.3 (6.9–14.3) vs. 13.5 (9.5–23.3) %]
and the medium-term [TE: 0.16 (0.12–0.25) vs. 0.19 (0.14–Table 4
Medium-term (4–6 weeks) test–retest reproducibility from baseline (T1–T3) of CPE
Variable N Change in the mean p-Value
Lung function
FVC (L) 13 −0.08 0.09
FEV1 (L) 13 −0.07 0.07
Maximal exercise parameters
_VO2max (L∙min−1) 13 −0.09 0.21
HRpeak (b∙min−1) 11 −5 0.49
SaO2 (%) 13 1 0.60
RPE 13 0.3 0.22
RPD 13 0.3 0.68
Ramp peak power output (W) 13 −12 0.05
Submaximal parameters
GET (L∙min−1) 12 0.05 0.40
MRT (s) 11 16 0.12
_VO2 gain (mL·min−1·W−1) 12 −0.28 0.72
OUES100 (mL·min
−1·logL−1) 12 −4.29 0.92
OUESGET (mL·min
−1·logL−1) 12 −40.69 0.61
_VE/ _VCO2-slope 12 −2.00 0.32
_VE/ _VO2 at the GET 12 −0.47 0.72
_VE/ _VCO2 at the GET 12 −0.12 0.90
Values are reported as means (95% confidence limits). TE, typical error; TECV%,
correlation coefficient. See Table 2 for list of abbreviations for exercise outcomes.0.32) L·min−1; TECV%: 13.3 (9.9–20.9) vs. 15.5 (10.9–26.9) %]
when compared with a ramp test in isolation.
4. Discussion
The principle finding of this study was that CPET was
reproducible when determining _VO2max [short-term (T1–T2) ICC:
0.94; medium-term (T1–T3) ICC: 0.93], with no significantT derived measures.
TE (95% CL) TECV% (95% CL) ICC p-Value
0.11 (0.08–0.16) 3.4 (2.6–5.2) 0.99 b0.01
0.08 (0.06–0.12) 3.4 (2.5–5.1) 0.99 b0.01
0.16 (0.12–0.25) 13.3 (9.9–20.9) 0.93 b0.01
14 (10–22) 7.8 (5.7–12.7) 0.30 0.38
3 (2–5) 3.1 (2.2–5.2) −0.28 0.40
0.6 (0.5–0.9) 7.6 (5.7–11.8) 0.85 b0.01
1.9 (1.4–2.8) 38.5 (27.9–63.8) 0.47 0.13
14 (11–22) 19.8 (14.7–31.6) 0.95 b0.01
0.14 (0.11–0.22) 16.8 (12.3–27.2) 0.74 0.01
22 (16–34) 89.0 (60.1–175.8) 0.25 0.48
1.85 (1.31–3.15) 24.5 (16.8–45.0) 0.24 0.40
107.28 (80.21–166.35) 15.3 (11.3–24.7) 0.80 b0.01
188.78 (141.15–292.73) 45.4 (32.3–78.6) 0.69 0.01
4.66 (3.49–7.23) 17.7 (12.9–28.7) 0.13 0.71
3.13 (2.34–4.86) 10.1 (7.4–16.0) 0.66 0.03
2.38 (1.78–3.69) 9.4 (6.9–14.9) 0.79 b0.01
TE expressed as a percentage of the coefficient of variation; ICC, intra-class
Fig. 1. Line of identity plot for _VO2max over both the short- [48 h (A)] and the medium-term [4–6 weeks (B)].
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(Δ9%) and 160 mL (Δ13.3%). Of the additional maximal
parameters, HR (3.2%, 7.8%), SaO2% (2.2%, 3.1%) and RPE
(7.8%, 7.6%) appear to hold acceptable short- and medium-term
reproducibility, respectively. Submaximal measures were identi-
fiable in most cases, with the _VE/ _VCO2-slope (7.8%), _VE/ _VCO2 at
the GET (8.8%), _VE/ _VO2 at the GET (10.2%), the GET (11.2%)
and OUES100 (12.0%) demonstrating promising reproducibility
over 48 h. However, an increased TEcv% was observed for sub-
maximal parameters at 4–6 weeks, with three ( _VO2 gain,
OUESGET, _VO2 MRT) TEs increasing above 20% (24.5%,
45.4%, 89.0%, respectively). Excluding the latter two variables
(OUESGET and _VO2 MRT), good short- and medium-term
agreement was observed for all measures, highlighting the
potential for CPET outcomes to be used to monitor disease
progression and/or the effect of therapeutic interventions.
Our data contribute significantly to the literature because the
reproducibility of _VO2max has not been established in CF using a
valid protocol. Reproducibility over time is crucial when eval-
uating the efficacy of treatments (e.g. antimicrobials, mucolytics
and gene mutation targeted therapies) which may accrue over
weeks or months, as well as monitoring exercise training inter-
ventions (4–6 weeks). To our knowledge, only one study has
examined the reproducibility of Smax verified (treadmill) _VO2peak
in a paediatric clinical population [15], reporting an 8.2%
(100 mL) variation in young spina bifida patients over a
2 week period. Using a solitary traditional ramp test, variations
of 6.9% [6] and 8.5% [16] have been reported over 4 weeks in CF
adults for _VO2peak. The reproducibility estimate for _VO2max in the
present study is therefore similar (9.3% and 13.3%) to these
earlier studies [6,16] and confirms CPET as a reproducible
assessment tool. Whilst the compromised validity of performing
traditional ramp tests, such as the popular Gofrey protocol, in
isolation has previously been demonstrated [2] and substantiated
herein, the present study in paediatric CF patients also highlights
a larger within-subject variation in _VO2max over both the short-
term (13.5 vs. 9.3%) and the medium-term (15.5 vs. 13.3%)when
compared with the combined ramp and Smax approach. Only one
study [5] has previously investigated CPET reproducibility in CFchildren, but is limited due to methodological concerns. Firstly,
only three outcome measures (peak power output, SaO2% and
HR) were obtained, offering limited interpretation of aerobic
fitness. Moreover, an intermittent sprint cycle test preceded the
ramp test, which likely caused fatigue and may explain, in part,
their low ramp test duration (~4 min).
Outcome measures which can assess patients' ability to
perform at intensities similar to activities of daily living are also
important. Submaximal measures hold specific value when
maximal exercise performance is limited by ventilatory capacity
and/or effort [2,4]. Furthermore, the GET can improve indepen-
dent of _VO2max [e.g. 12,17] and facilitates the identification of
individualised exercise intensities within specific intensity
domains (i.e. at a %GET or %Δ) for young CF patients [e.g.
18]. The present study employed a cluster of measures and two
independent observers to identify the GET in 12 of 13 (92%)
patients for all tests, with TE of 11.2% (or 110 mL) and 16.8%
(or 140 mL) over the short- and the medium-term, respectively.
Using similar methodology, our laboratory has previously
reported a similar GET detection rate (100%) in healthy children,
with a reproducibility estimate of ~8% [19]. The present findings
challenge previous reports suggesting difficulties in non-
invasively detecting the GET and ventilatory threshold in patients
with chronic respiratory disease and airflow limitation [e.g. 20],
likely due to the mild disease severity and subsequently normal
ventilatory drive of our patients. The _VO2 gain was associated
with reasonable TE of 17.4% and 24.5% over the short- and the
medium-term, respectively. The _VO2 MRT was associated with
considerably greater short- (49.1%) and medium-term (89.0%)
variation. These submaximal measures, especially the MRT, may
therefore be less useful than the GET.
Ventilatory efficiency is best described by relating _VO2 and
_VCO2 dynamics to _VE [21]. The _VE– _VO2 relationship is
optimally described through the OUES [21], which is theoreti-
cally resistant to early test termination and intra- and inter-
observed variability [22]. In the current study, OUES100 was
detectable in all tests and the OUESGET detectable in all patients
at T1 and 92% at T2 and T3. Short- and medium-term TEs of
12.0% and 15.3% were associated with the OUES100, compared
649Z.L. Saynor et al. / Journal of Cystic Fibrosis 12 (2013) 644–650with 8.3% documented in adult CF patients over a 4 week period
[16]. Similar variations of 7.8% and 17.7% were documented for
the _VE/ _VCO2-slope in the present study. As the OUESGET was
associated with increased short- (17.9%) and medium-term
(45.4%) error and lower detection rate compared to the
OUES100, the OUES100 appears a more robust outcome measure.
The present study provides the reproducibility for maximal
and submaximal parameters over the short- and the medium-
term. Our data denote that _VO2max changes exceeding 9%
(150 mL) and 13% (160 mL) may indicate a change attributable
to therapeutic intervention or disease progression over the short-
and the medium-term, respectively. The TE must, however, be
considered relative to an established smallest worthwhile change
(SWC), to estimate how many participants are needed to observe
a ‘meaningful’ effect [7,8,24].
Using Hopkins' formula [7] for the estimation of sample size
[n = 8(CV2/d2)], CV and d can be substituted for TE and SWC,
respectively. Whilst the present study has documented the CV,
the value of d is uncertain for CPET outcomes in CF. Cox and
Elkins [23] recently raised concerns regarding how ‘clinically
worthwhile’ exercise training interventions are for patients with
CF, given that the SWC for outcome measures had yet to be
established. However, the mean annual rate of _VO2max decline
could, for example, be used to determine the SWC in _VO2max,
since it reportedly predicts CF patient survival [29]. Using
Pianosi and colleagues' [29] annual _VO2max decline and the
fitness of our similarly aged patients, a ~6% increase in _VO2max
relative to baseline fitness would be required to prevent a
meaningful drop in prognostic stratification. Using 6% as the
SWC and a 13.3% TE, 5 patients would be required to detect a
change in _VO2max from a 4–6 week intervention that would be
considered meaningful and clinically worthwhile.
Determining the extent to which changes in outcome
measurements relate to a given reference measure is essential to
the clinical utility of CPET. Responsiveness to intervention has
been conceptually described as a signal-to-noise ratio [7,8,24],
whereby the TE represents the ‘noise’ and any intervention-
induced effect, the ‘signal’. Data concerning _VO2max responsive-
ness within CF are sparse [25]. Of the available evidence, studies
have reported training-related improvements in _VO2max ranging
from ~10 to 20% [e.g. 26,27,28]. Using our established long-term
TE, the aerobic training improvement could be considered
meaningful with a signal-to-noise ratio of ~1.5:1.0 for a ~20%
improvement, but questionable, with a signal to noise ratio of
~0.8:1.0 for a 10% improvement. Unfortunately, the signal-to-
noise ratio for most parameters is unknown. If future intervention
studies provided more comprehensive CPET data, this would
permit more informed data interpretation, as researchers could
select measurements with higher signal-to-noise ratios, whilst
also considering their sensitivity.
Standardising CPET procedures will enable a larger empirical
database of CF patients to accumulate and, longitudinally,
enhance our understanding of the link between physiological
dysfunction during exercise and patients' prognostic stratifica-
tion. Whilst _VO2peak possesses recognised prognostic value [3],
the _VE/ _VCO2-slope and OUES have demonstrated superior
prognostic information in other clinical populations [e.g. 21,30]and warrant investigation in CF, particularly given that although
patients remained clinically stable throughout the present study,
increased medium-term noise was associated with submaximal
parameters. This may indicate value in detecting subtle clinical
changes, which current clinical assessments cannot. CPET to
assess therapeutic interventions also requires investigation.
In conclusion, _VO2max was reproducible over 48-h
(Δ150 mL; Δ9.3%) and 4–6 weeks (Δ160 mL; Δ13.3%).
Supplementary maximal and submaximal parameters should be
incorporated to comprehensively assess aerobic function. The
present study provides a reproducible CPET protocol for young
patients with mild-to-moderate CF and will inform sample size
and power calculations when planning interventional studies
that use cardiorespiratory fitness as an endpoint.
Conﬂicts of interest
There are no conflicts of interest to declare.
Acknowledgements
All authors read and approved the manuscript. CAW, ZLS and
ARB conceived and designed the study; ZLS and PJO
coordinated testing, whilst ZS completed the data collection;
ZLS and ARB analysed the data; CAW, ZS, ARB and PJO
partook in data interpretation; ZLS wrote the manuscript and
CAW, ARB and PO revised the manuscript; CAW acts as
guarantor. This study was supported by a small grant from the
RD&E. Gratitude is expressed to the NIHR Exeter Clinical
Research Facility, Owen Tomlinson, David Childs and the
RD&E CF team for their support throughout. Finally, we would
like to thank the patients who kindly volunteered their time to be
involved.
References
[1] Bradley JM, Madge S, Morton AM, Quittner AL, Elborn JS. Cystic
fibrosis research in allied health and nursing professions. J Cyst Fibros
2012;11(5):387–92.
[2] Barker AR, Williams CA, Oades PJ, Saynor ZL. A protocol to determine
valid _VO2max in young cystic fibrosis patients. J Sci Med Sport 2013, http://
dx.doi.org/10.1016/j.jsams.2013.01.010 (in press).
[3] Nixon PA, Orenstein DM, Kelsey SF, Doershuk CF. The prognostic value of
exercise testing in patients with cystic fibrosis. N Engl J Med 1992;327(25):
1785–8.
[4] Baba R, Nagashima M, Goto M, Nagano Y, Yokota M, Tauchi N, et al.
Oxygen uptake efficiency slope, a new index of cardiorespiratory functional
reserve derived from the relation between oxygen uptake and minute
ventilation during incremental exercise. J Am Coll Cardiol 1996;28(2):
1567–72.
[5] Kent L, O'Neill B, Davidson G, Nevill A, Murray J, Reid A, et al. Cycle
ergometer tests in children with cystic fibrosis: reliability and feasibility.
Pediatr Pulmonol 2012;47(12):1226–34.
[6] McKone EF, Barry SC, Fitzgerald MX, Gallagher CG. Reproducibility of
maximal exercise ergometer testing in patients with cystic fibrosis. Chest
1999;116(2):363–8.
[7] Hopkins WG. Measures of reliability in sports medicine and science.
Sports Med 2000;30(1):1–15.
[8] Atkinson G, Nevill AM. Statistical methods for assessing measurement
error (reliability) in variables relevant to sports medicine. Sports Med
1998;26(4):217–38.
650 Z.L. Saynor et al. / Journal of Cystic Fibrosis 12 (2013) 644–650[9] Schwachman H, Kulczychi LL. Long-term study of one hundred five
patients with cystic fibrosis; studies made over a five- to fourteen-year
period. AMA J Dis Child 1958;96(1):6–15.
[10] Quanjer P. Standardized lung function testing. Report of the Working Party
for the European Community Coal and Steel. Eur Respir J 1993;6:13–1025.
[11] Beaver WL, Wasserman K, Whipp BJ. A new method for detecting
anaerobic threshold by gas exchange. J Appl Physiol 1986;60(6):2020–7.
[12] Wasserman K. The anaerobic threshold measurement to evaluate exercise
performance.Am Rev Respir Dis 1984;126:S35–40 [Suppl.].
[13] Tabet JY, Beauvais F, Thabut G, Tartiere JM, Logeart D, Cohen-Solol A.
Critical appraisal of the prognostic value of the VE/VCO2 slope in chronic
heart failure. Eur J Cardiovasc Prev Rehabil 2003;10(4):267–72.
[14] Hopkins WG. A new view of statistics.Internet Society for Sport Science;
2000 [http://sportsci.org/resource/stats].
[15] de Groot JF, Takken T, Gooskens RH, Schoenmakers MA, Wubbels M,
Vanhees L, et al. Reproducibility of maximum and submaximal exercise
testing in “normal ambulatory” and “community ambulatory” children and
adolescents with spina bifida: which is best for the evaluation and
application of exercise training? Phys Ther 2011;91(1):267–76.
[16] Gruet J, Brisswalter J, Mely L, Vallier JM. Clinical utility of the oxygen
uptake efficiency slope in cystic fibrosis patients. J Cyst Fibros 2010;9(5):
307–13.
[17] Casaburi R, Patessio A, Ioli F, Zanaboni S, Donner CF, Wasserman K.
Reductions in lactic acidosis and ventilation as a result of exercise training in
patients with obstructive lung disease. AmRevRespir Dis 1991;143(1):9–18.
[18] Stevens D, Oades PJ, Armstrong N, Williams CA. Exercise metabolism
during moderate-intensity exercise in children with cystic fibrosis following
heavy-intensity exercise. Appl Physiol Nutr Metab 2011;36(6):920–7.
[19] Fawkner SG, Armstrong N, Childs DJ, Welsman JR. Reliability of the
visually identified ventilatory threshold and the V-slope in children. PES
2002;14:181–92.[20] Sexauer WP, Cheng HK, Fiel SB. Utility of the breathing reserve index at
the anaerobic threshold in determining ventilatory-limited exercise in adult
cystic fibrosis patients. Chest 2003;124(4):1469–75.
[21] Arena R, Guazzi M, Myers J, Chase P, Bensimhon D, Cahalin LP, et al. The
relationship between minute ventilation and oxygen consumption in heart
failure: comparing peak VE/VO2 and the oxygen uptake efficiency slope. Int
J Cardiol 2011;154(3):384–5.
[22] Akkerman M, van Brussel M, Hulzebos HJ, Vanhees L, Helders PJM,
Takken T. The oxygen uptake efficiency slope: what do we know?
J Cardiopulm Rehabil Prev 2010;30(6):357–73.
[23] Cox NS, Elkins MR. Physical training has several benefits for people with
cystic fibrosis. Br J Sports Med 2011;45(10):835–6.
[24] de Vet HC, Terwee CB, Knol DL, Bouter LM. When to use agreement
versus reliability measures. J Clin Epidemiol 2006;59(10):1033–9.
[25] Bradley JM, Moran F. Physical training for cystic fibrosis. Cochrane
Database Syst Rev 2009;23(1):CD002768.
[26] Selvadurai HC, Blimkie CJ, Meyers N, Mellis CM, Cooper PJ, Van Asperen
PP. Randomized controlled study of in-hospital exercise training programs in
children with cystic fibrosis. Pediatr Pulmonol 2002;33(3):194–200.
[27] Hulzebos HJ, Sneider H, van der Net J, Helders PJM, Takken T.
High-intensity interval training in an adolescent with cystic fibrosis: a
physiological perspective. Physiother Theory Pract 2010;27(3):231–7.
[28] Hebestreit H, Kieser S, Junge S, Ballmann M, Hebestreit A, Schindler C,
et al. Long-term effects of a partially supervised conditioning programme
in cystic fibrosis. Eur Respir J 2010;35(3):578–83.
[29] Pianosi P, LeBlanc J, Almudevar A. Peak oxygen uptake in children with
cystic fibrosis. Thorax 2005;60(1):50–4.
[30] Kasikcioglu E, Toker A, Tanju S, Arzuman P, Kayserilioglu A, Dilege S,
et al. Oxygen uptake kinetics during cardiopulmonary exercise testing and
postoperative complications in patients with lung cancer. Lung Cancer
2009;66(1):85–8.
